683 Capital Management’s Vaxart VXRT Stock Holding History

683 Capital Management’s Portfolio VXRT Stock Details VXRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-15,662	Closed	-$1.05M	–	61
2014 Q1	$1.05M	Sell	15,662 -25,247	-62%	-$1.56M	0.41%	41
2013 Q4	$1.89M	Hold	40,909	–	–	0.54%	41
2013 Q3	$1.88M	Hold	40,909	–	–	0.48%	41
2013 Q2	$1.55M	Buy	+40,909	New	+$1.7M	0.52%	40

Other funds holding VXRT

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

683 Capital Management's VXRT Position: Q2 2014 in Review

683 Capital Management sold out of Vaxart (VXRT) in Q2 2014, closing a stake of 15,662 shares — an estimated $1.05M sold.

683 Capital Management first reported a position in VXRT in Q2 2013 and held it in 4 quarters. The position peaked at $1.89M in Q4 2013. 58 funds tracked by Wall St. Rank hold VXRT as of Q2 2014.

683 Capital Management reported no remaining Vaxart position as of Q2 2014 after selling out during the quarter.
683 Capital Management sold 15,662 Vaxart shares in Q2 2014, an estimated $1.05M.
683 Capital Management first reported a position in Vaxart in Q2 2013 and held it in 4 quarters.
683 Capital Management's Vaxart position peaked at $1.89M in Q4 2013.
58 funds tracked by Wall St. Rank held Vaxart as of Q2 2014.

Based on 683 Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.